<DOC>
	<DOCNO>NCT01393184</DOCNO>
	<brief_summary>Radiotherapy alone generally treatment old patient SCCHN . No evidence indicate combination EGFR Target therapy bring benefit patient . Senile Society come China , mean age Beijing reach 80 year old . A valuable treatment efficacy safety need senile patient SCCHN . The purpose study `` Prospective , Randomized , Controlled , Phase II Multiple Centered Clinical Trial Nimotuzumab Combined Radiotherapy Senile Locally Advanced SCCHN '' sponsor evaluate efficacy safety Nimotuzumab Combined Radiotherapy Senile SCCHN patient .</brief_summary>
	<brief_title>Safety Efficacy Study Target Therapy Combined With Radiotherapy Treat Senile Locally Advanced SCCHN</brief_title>
	<detailed_description>condition : Senile Locally Advanced SCCHN . Intervention : Drug : Nimotuzumab . Arm A : Radiotherapy+Nimotuzumab ; Arm B : Radiotherapy alone . Phase : Phase 2</detailed_description>
	<criteria>Informed consent form Age 6585，both gender HNSCC Confirmed pathology Primary site oral cavity , oropharynx , hypopharynx , larynx Stage Ⅲ/ⅣA , B Primary lesion measure Karnofsky 's Performance Scale ≥60 Life expectancy 6 month Haemoglobin≥100g/L , WBC ≥3.5×109/L , platelet count≥90×109/L Hepatic function : ALT、AST &lt; 1.5 x ULN , TBIL &lt; 1.5 x ULN Renal function : Creatinine &lt; 1.5 x ULN Received anti EGFR monoclonal antibody treatment Previous chemotherapy radiotherapy Participation interventional clinical trial within 1 month Other malignant tumor ( except nonmelanoma skin Cancer carcinoma situ cervix ) History serious allergic allergy History Serious lung heart disease</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Target therapy</keyword>
</DOC>